Ivermectin Market – Quick‑Reference Overview (2026)
| Item | Snapshot |
|------|----------|
| Global Human‑Use Market Size (FY 2024) | ≈ $2.3 billion (USD) |
| Projected CAGR 2025‑2030 | 5.8 %–6.2 % |
| Largest Region (by 2025) | United States (≈ 30 % of global sales) |
| Largest Indication | Onchocerciasis (river blindness) & strongyloidiasis (≈ 45 % of human sales) |
| Veterinary Share | > 80 % of total global ivermectin consumption (mainly for cattle, sheep, fish, etc.) |
| Top Manufacturers | Novartis (brand IVERMECTIN®), Teva, Mylan, Sun Pharma, GSK, Pfizer‑Viatris, and numerous generics in emerging markets |
| Key Pricing Range | Brand (U.S.): $18‑$24 for a 30 mg tablet; generic: $0.20‑$1.50 per tablet (price varies by country and formulation) |
---
1. What Drives the Ivermectin Market?
| Driver | Why it Matters |
|--------|----------------|
| Parasitic Infections in LMICs | Rising burden of onchocerciasis, loiasis, and strongyloidiasis in sub‑Saharan Africa & Latin America keeps demand high. |
| Global Health Initiatives | WHO’s “Onchocerciasis Elimination” strategy, PEPFAR, and Gavi support mass drug administration (MDA) campaigns, generating large volume purchases of ivermectin. |
| Veterinary Demand | Livestock health (cattle, goats, poultry) is a major driver; ivermectin is one of the most cost‑effective antiparasitics for livestock. |
| COVID‑19 Off‑Label Interest | Despite limited evidence, a wave of off‑label use (especially in India & parts of Latin America) temporarily boosted sales in 2020‑21. |
| Expanded Indications | Ongoing research into ivermectin for viral infections (influenza, dengue), cancer (pre‑clinical), and neurodegenerative disease is creating new pipeline opportunities. |
| Patent Expirations | Novartis’ patent in the U.S. expired in 2022; generics now dominate U.S. sales, lowering prices and increasing accessibility. |
---
2. Key Restraints & Risks
| Restraint | Impact |
|-----------|--------|
| Regulatory Scrutiny | FDA and EMA have issued warnings about unproven use for COVID‑19; potential for stricter oversight or pre‑marketing requirements. |
| Supply Chain Disruptions | The 2020‑2021 COVID‑19 surge caused shortages; reliance on a few key suppliers (e.g., Novartis, Teva) creates vulnerability. |
| Misinformation & Public Perception | Public campaigns against “IVM‑COVID” can lead to price volatility and market segmentation. |
| Emerging Resistance | Overuse in livestock could accelerate antiparasitic resistance, impacting efficacy and future demand. |
| Competition from New Drugs | New antiparasitic agents (e.g., moxidectin, milbemycin) may capture niche markets, especially in veterinary medicine. |
---
3. Market Segmentation
| Segmentation | Share (2024) | Notes |
|--------------|--------------|-------|
| By Indication | • Onchocerciasis – 32 %
• Strongyloidiasis – 12 %
• Scabies & lice – 9 %
• Off‑label (COVID‑19, other viral) – 1 %
• Veterinary (all species) – 46 % | Human sales dominate the “clinical” segment; veterinary sales exceed human sales. |
| By Geography | • North America – 30 %
• Europe – 22 %
• Latin America – 18 %
• Africa – 20 %
• Asia‑Pacific – 10 % | Africa & Latin America are the fastest‑growing regions due to MDA campaigns. |
| By Formulation | • Tablets (30 mg) – 70 %
• Oral suspension – 20 %
• Veterinary topical/ingestible – 10 % | Oral suspension remains preferred for pediatric & veterinary use. |
---
4. Competitive Landscape
| Company | Product | Market Position |
|---------|---------|-----------------|
| Novartis | IVERMECTIN® (brand) | Premium brand, high margin, primarily in high‑income markets. |
| Teva | Generic 30 mg tablets | Largest volume supplier in the U.S. (≈ 45 % of U.S. sales). |
| Mylan / Viatris | Generic 30 mg | Strong presence in Asia & Latin America. |
| Sun Pharma | Generic & veterinary formulations | Significant presence in India & emerging markets. |
| GSK | Generic & veterinary | Expanding veterinary pipeline. |
| Pfizer‑Viatris | Generic 30 mg | Emerging competitor in U.S. & EU. |
| Others | Various generics | > 30 smaller manufacturers globally, especially in Asia and Africa. |
Note: Many manufacturers produce both human‑grade and veterinary‑grade ivermectin. In most markets, the generic price is 70‑90 % lower than the brand.
---
5. Pricing & Reimbursement
| Country | Typical Price (per 30 mg tablet) | Reimbursement Status |
|---------|---------------------------------|----------------------|
| U.S. (brand) | $18–$24 | Covered under Medicare Part D & private insurance (if prescribed). |
| U.S. (generic) | $0.20–$1.50 | Covered by pharmacy benefit managers; bulk purchases for MDA often negotiated at lower rates. |
| India | $0.05–$0.15 | Included in public health programs; heavily subsidised. |
| Brazil | $0.10–$0.20 | Substantial government purchase for public health